CRIS Current Research Information System

GELSOMINO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 550
NA - Nord America 429
AS - Asia 335
AF - Africa 73
SA - Sud America 3
OC - Oceania 2
Totale 1.392
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 427
IT - Italia 308
SG - Singapore 137
CN - Cina 115
SE - Svezia 49
IE - Irlanda 43
IN - India 40
DE - Germania 39
CH - Svizzera 30
CI - Costa d'Avorio 30
TG - Togo 28
GB - Regno Unito 26
JO - Giordania 18
FI - Finlandia 17
BG - Bulgaria 14
NG - Nigeria 13
HK - Hong Kong 11
RU - Federazione Russa 9
ID - Indonesia 7
ES - Italia 6
NL - Olanda 5
PK - Pakistan 3
AU - Australia 2
CA - Canada 2
FR - Francia 2
JP - Giappone 2
SC - Seychelles 2
TW - Taiwan 2
AR - Argentina 1
BR - Brasile 1
CO - Colombia 1
LT - Lituania 1
PL - Polonia 1
Totale 1.392
Salva come PNG Salva come JPEG
Città #
Singapore 125
Bologna 77
Santa Clara 64
Dublin 43
Chandler 38
Boardman 37
Ashburn 31
Abidjan 30
Lomé 28
Bern 27
Milan 27
Vicenza 24
Cinquefrondi 22
Amman 18
Beijing 17
Messina 16
Helsinki 15
Hyderabad 15
New York 14
Sofia 14
Abeokuta 13
Southend 13
Fairfield 12
Princeton 12
Turin 12
Seattle 10
Hong Kong 8
Boydton 7
Houston 7
Jakarta 7
London 7
Ferrara 6
Guangzhou 6
Redmond 6
Berlin 5
Cesena 5
Palermo 4
Seville 4
Shanghai 4
Wilmington 4
Amsterdam 3
Bühl 3
Castenaso 3
Diamante 3
Florence 3
Jinan 3
Luco dei Marsi 3
Paola 3
Woodbridge 3
Baricella 2
Bisceglie 2
Borgomanero 2
Brunswick 2
Cambridge 2
Casalecchio di Reno 2
Changsha 2
Cosenza 2
Foshan 2
Jiangmen 2
Karachi 2
Lappeenranta 2
Los Angeles 2
Melbourne 2
Montelupone 2
Monza 2
Naples 2
Padova 2
Paris 2
Phoenix 2
Prineville 2
Rome 2
S. Pietro 2
Saitama 2
San Diego 2
Shijiazhuang 2
Springfield 2
Taipei 2
Tarragona 2
Toronto 2
Xi'an 2
Ann Arbor 1
Baoding 1
Bedford 1
Berra 1
Buenos Aires 1
Carlentini 1
Castelnuovo Rangone 1
Chelsea 1
Chicago 1
Chongqing 1
Collegeville 1
Correggio 1
Costa Volpino 1
Cotignola 1
Dallas 1
Falkenstein 1
Forlì 1
Formigine 1
Garden City 1
Hamburg 1
Totale 943
Salva come PNG Salva come JPEG
Nome #
A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale 135
Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches 114
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience 95
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 83
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution 73
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors 73
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis 54
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC 52
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 52
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 51
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 47
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy 46
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis 46
Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation 40
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination 39
Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis 38
Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database 38
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? 34
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) 33
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors 33
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib 32
Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review 32
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 31
The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer 24
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY 23
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) 19
Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3) 18
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) 15
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis 15
Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report 13
Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors 13
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 10
Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report 10
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 10
Ad(aura): a fresh breeze for patients with resected EGFR-mutant non-small cell lung cancer 10
A new classification of upper gastrointestinal toxicity induced by immunotherapy: from endoscopic and pathological insights to clinical management 9
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome 9
Totale 1.469
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.395
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.395
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022186 0 10 2 15 3 2 0 54 8 8 58 26
2022/2023530 14 39 19 19 89 41 45 37 110 23 29 65
2023/2024255 17 16 11 23 19 52 9 31 6 36 31 4
2024/2025498 54 77 84 92 131 60 0 0 0 0 0 0
Totale 1.469